Rabeprazole 20 mg for erosive esophagitis-associated symptoms in a large, community-based study: additional results.

Abstract

PURPOSE:

To provide additional efficacy data in patients treated with rabeprazole through week 4, and to validate sustained relief of gastroesophageal reflux disease symptoms through week 8 as well as to further analyze rabeprazole safety in patients with wide-ranging demographic and clinical characteristics.

RESULTS:

Patients in this study (N = 2,449) demonstrated significant overall improvement versus baseline (P < 0.001). Substantial symptom relief was seen throughout 8 weeks of treatment. By week 4, complete relief of daytime and nighttime heartburn, belching, regurgitation, and dysphagia was observed in 87.5, 90.7, 50.7, 77.6, and 75.1% of patients, respectively. Improvements were seen in rabeprazole-treated patients (<65 or >or=65 years) with a range of baseline symptom severities and across different racial groups. Rabeprazole was well tolerated.

CONCLUSIONS:

In patients with endoscopy-confirmed erosive esophagitis treated with once-daily rabeprazole 20 mg, prompt and continuing improvements were seen in daytime and nighttime heartburn, belching, regurgitation, and dysphagia.

• Authors: Alan Cutler, Malcolm Robinson, Anita Murthy, Byron Delemos
• Journal: Digestive diseases and sciences (Dig Dis Sci) Vol. 55 Issue 2 Pg. 338-45 (Feb 2010) ISSN: 1573-2568 [Electronic] United States
• PMID: 19557517 (Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• 2-Pyridinylmethylsulfinylbenzimidazoles
• Enzyme Inhibitors
• Rabeprazole
• Proton-Translocating ATPases

Topics

• 2-Pyridinylmethylsulfinylbenzimidazoles (administration & dosage)
• Aged
• Dose-Response Relationship, Drug
• Endoscopy, Gastrointestinal
• Enzyme Inhibitors (administration & dosage)
• Esophagitis, Peptic (complications, diagnosis, drug therapy)
• Female
• Follow-Up Studies
• Heartburn (drug therapy, epidemiology, etiology)
• Humans
• Incidence
• Male
• Middle Aged
• Proton-Translocating ATPases (antagonists & inhibitors)
• Rabeprazole
• Time Factors
• Treatment Outcome
• United States (epidemiology)